程志刚++++++梁萍++++++于晓玲++++++韩治宇++++++刘方义++++++于杰++++++陈洪峰

    [摘要] 目的 评价超声引导经皮微波消融治疗T1a期肾癌的临床应用价值。 方法 回顾性研究解放军总医院2012年1月～2013年12月44例T1a期肾癌患者共计48枚肿瘤的微波消融治疗资料，肿瘤最大径平均为(2.79±0.75)cm。记录并处理术后并发症和副作用。术后平均随访(18.1±9.3)个月，通过临床资料及影像检查评价疗效。 结果 88.6%(39/44)的患者一次消融完成治疗，11.4%(5/44)的患者两次消融完成治疗。术后出现严重并发症结肠穿孔1例(2.3%)，轻微并发症和副作用分别为7例(15.9%)和8例(18.2%)。97.7%(43/44)的患者消融治疗后无局部复发和远处转移表现。1例(2.3%)患者因肿瘤进展死亡。2例肾功能不全的患者在透析治疗辅助下安全有效完成了消融治疗。 结论 超声引导经皮微波消融治疗是T1a期肾癌患者的一种安全、有效的微创治疗方法。

    [关键词] 超声引导；微波；消融；肾癌

    [中图分类号] R737.11 [文献标识码] A [文章编号] 1673-7210(2017)02(b)-0086-05

    [Abstract] Objective To evaluate the value of percutaneous microwave ablation (MWA) treatment for kidney tumors at T1a stage under ultrasound (US) guidance. Methods From January 2012 to December 2013 in Chinese PLA General Hospital， the clinical data of 44 patients with 48 renal tumors proven histopathologically were retrospectively analyzed， whose tumors were performed the procedure of US-guided percutaneous MWA. The mean maximal diameter of the tumors was (2.79±0.75) cm， and the mean follow-up period was (18.1±9.3) months. The complications and side effects following the procedure were observed and treated ......